KROS

Keros Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-04

Figures on this page computed 2026-11-08 12:40 UTC

Last close

10.83USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-04

4.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
35.7%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
43.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-08-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

6.87x

-1.46x

-2.32x

n/a

0.29x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-04

Sales6.87x
Its own average over 8 years, 35.5M.
Profit-1.46x
Its own average over 8 years, -59.5M.
Free cash flow-2.32x
Its own average over 8 years, -45.6M.
Debtn/a
Its own average over 2 years, 9.8M.
Price0.29x
Its own average over 7 years, 38. Market data, 2026-11-04

Sales is furthest from its own average, at 6.87 times.

Sales is 6.87 times its own 8-year average; Profit is -1.46 times its own 8-year average; Free cash flow is -2.32 times its own 8-year average; Price is 0.29 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-04

Sales against its own 8-year average6.87
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
The filing itself
Profit against its own 8-year average-1.46
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
The filing itself
Free cash flow against its own 8-year average-2.32
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
The filing itself
Debt against its own 2-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001664710-26-000018
Reported in
USD
The filing itself
Price against its own 7-year average0.29Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD